Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source..
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2258242-opium-opioid-addiction-pipeline-review-h2-2017
Top Companies mentioned
iX Biopharma Ltd
Nemus Bioscience Inc
Opium (Opioid) Addiction Industry Major Outlook
Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 6, 5, 7, 12 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.
Opium (Opioid) Addiction pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Opium (Opioid) Addiction - Competitive Analysis
Key players are making innovative developments in Opium (Opioid) Addiction industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector
The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction .
The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Opium (Opioid) Addiction therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Opium (Opioid) Addiction therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction .
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2258242-opium-opioid-addiction-pipeline-review-h2-2017
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
P: +44 208 133 9349
M: +1 646 845 9349